Oxaliplatin PhaRes 5 mg/ml (IV Infusion)

50 ml vial: ৳ 3,500.00

Medicine Details

Category Details
Generic Oxaliplatin
Company Thymoorgan pharmazie gmbh germany

Title

  • Oxaliplatin PhaRes PhaRes

Categories

  • Chemotherapy
  • Oncology
  • Cancer Treatment

Description

  • Used for adjuvant treatment of stage III colon cancer and treatment of advanced colorectal cancer
  • Undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand
  • Forms both inter-and intrastrand Pt-DNA crosslinks, inhibiting DNA replication and transcription
  • Exhibits in vitro and in vivo antiproliferative activity in several tumor models
  • Administered in combination with 5-fluorouracil/folinic acid every 2 weeks for advanced disease
  • Administered for a total of 6 months (12 cycles) for adjuvant use
  • No specific cytochrome P-450-based drug interaction studies conducted
  • Clearance of platinum-containing species may be decreased by coadministration of potentially nephrotoxic compounds
  • Contraindicated in patients with known allergy to oxaliplatin or other platinum compounds
  • Most common adverse reactions include peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis
  • Pregnancy Category D with potential fetal harm, and unknown excretion in human milk
  • Hypersensitivity reactions, neurological toxicity, pulmonary toxicity, hepatotoxicity, and cardiovascular toxicity should be carefully monitored
  • No known antidote for oxaliplatin overdose, with anticipated complications including hypersensitivity reaction, myelosuppression, nausea, vomiting, diarrhea, and neurotoxicity
  • Therapeutic Class: Cytotoxic Chemotherapy
  • Store in a cool & dry place, protected from light and moisture

Dosage & Administration

  • Administered in combination with 5-fluorouracil/folinic acid every 2 weeks for advanced disease
  • Administered for a total of 6 months (12 cycles) for adjuvant use
  • Day 1: Oxaliplatin 85 mg/m² intravenous infusion, folinic acid 200 mg/m² intravenous infusion, and 5-fluorouracil intravenous bolus and infusion
  • Day 2: Folinic acid 200 mg/m² intravenous infusion, and 5-fluorouracil intravenous bolus and infusion

Pharmacology

  • Undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand
  • Forms both inter-and intrastrand Pt-DNA crosslinks, inhibiting DNA replication and transcription
  • Exhibits in vitro and in vivo antiproliferative activity in several tumor models

Interaction

  • No specific cytochrome P-450-based drug interaction studies conducted
  • Clearance of platinum-containing species may be decreased by coadministration of potentially nephrotoxic compounds

Contraindications

  • Contraindicated in patients with known allergy to oxaliplatin or other platinum compounds

Side Effects

  • Peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis

Pregnancy & Lactation

  • Pregnancy Category D with potential fetal harm
  • Unknown excretion in human milk

Precautions & Warnings

  • Grade 3/4 hypersensitivity reactions observed in 2-3% of colon cancer patients
  • Neurological, pulmonary, hepatotoxic, and cardiovascular toxicities should be carefully monitored

Overdose Effects

  • No known antidote for oxaliplatin overdose
  • Complications may include hypersensitivity reaction, myelosuppression, nausea, vomiting, diarrhea, and neurotoxicity

Therapeutic Class

  • Cytotoxic Chemotherapy

Storage Conditions

  • Store in a cool & dry place, protected from light and moisture

Related Brands